ArticleImmune network2025
Pediatric Atopic Dermatitis Exhibits Distinctive Patterns in JAK/STAT Pathway Activation and CD6-ALCAM Signaling.
Article in Immune network, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunological differences in atopic dermatitis across age groups: insights from single-cell multi-omics.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric atopic dermatitis (AD) shows distinct clinical characteristics compared to adult AD, suggesting unique inflammatory profiles that may influence disease prognosis and treatment response. We aimed to identify unique immune signatures of pediatric AD and investigate the differences between pediatric and adult AD patients. Nine pediatric (6-16 years) and 12 adult (20-60 years) were enrolled. PBMCs were collected from AD patients and age- and sex-matched healthy controls (HCs). Transcriptomic profiles were analyzed using single-cell RNA sequencing, and the immune phenotypes of adult and pediatric AD were compared. Th2 gene expression was elevated in both adult and pediatric AD, while Th1, Th17, and Th22 gene expression was downregulated in pediatric AD but not in adults. Genes involved in JAK/STAT signaling pathway, which were upregulated in adult AD, were not significantly increased in pediatric AD. The CD6-activated leukocyte cell adhesion molecule (ALCAM) pathway was upregulated in pediatric AD compared to pediatric HCs, but not in adult AD. Pediatric AD reveals distinct immune signatures, including a lack of JAK/STAT pathway upregulation observed in adult AD and a unique activation of the CD6-ALCAM pathway. These findings highlight the importance of age-specific treatment strategies in AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.